Modeling of Survival and Frequency of Cardiovascular-Related Hospitalization in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis

ConclusionsTafamidis reduced cumulative mortality and hospitalization risk versus placebo in patients with ATTR-CM. Baseline predictors of outcome were consistent with the cardiovascular nature of the disease and suggested that earlier treatment may improve outcomes.Clinical Trials.gov IdentifierNCT01994889 (date of registration: November 26, 2013).
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research